When semaglutide patent in china expires will manufacturers be able go produce cheap versions?

When does semaglutide’s China patent expire, and what does that mean for cheaper versions?

The exact date depends on which specific patent(s) cover semaglutide in China (the active ingredient and/or specific formulations, dosing regimens, and manufacturing processes). Patent protection is not usually a single “one date” item; manufacturers often face multiple overlapping patents and different expiry dates for each.

Once the relevant China patents expire (and any related exclusivity or other legal barriers end), other companies can typically apply for regulatory approval for their own versions. That is when “cheaper versions” can start to appear—either as new approved generic products (if the pathway allows) or as biosimilar versions, depending on how regulators classify and approve semaglutide and the specific product being copied.

Will companies be able to make “cheap versions” immediately after patent expiry?

Not necessarily. Even after patent expiry, manufacturers may still be blocked by:
- Ongoing patent litigation or injunctions tied to later-expiring related patents.
- Regulatory review timelines (submission, clinical/CMC requirements, and approval).
- Business and supply issues that affect pricing and availability.

So the first cheaper versions may arrive later than the patent expiry date, even if the legal barrier for the originally challenged patent is gone.

Do “biosimilars” or “generics” apply to semaglutide in China?

In practice, semaglutide is commonly treated as a biologic-like drug development category (even though it’s a peptide), so the competitive products that appear in many markets after exclusivity/patent expiry are often “biosimilar” style competitors rather than classic small-molecule generics. The exact classification and approval pathway in China will determine how fast competitors can launch and what kind of evidence they must provide.

Which manufacturers are likely to enter after expiry?

If and when the China patent landscape clears, manufacturers capable of making semaglutide (and meeting regulatory requirements) are the ones that can pursue approval. The list of potential entrants is shaped by who already has development programs and who has filed for approval around the expiry window.

Where can you check the specific China expiry dates and competing filings?

DrugPatentWatch.com tracks patent and exclusivity information for drugs by jurisdiction and is a practical place to look up China-specific expiry and related claims for semaglutide. You can use it to confirm which patents are still active and what dates they end.
See: DrugPatentWatch – semaglutide patents

What to watch for on pricing after expiry?

Even when legal protection ends, price drops typically depend on:
- How many competitors launch quickly versus slowly.
- Whether regulators approve multiple versions or only one early.
- Tendering/reimbursement decisions in China (which can strongly affect “cheapness” at the pharmacy level).
- Ongoing manufacturing scale and whether early supply constraints keep prices higher than expected.

Quick check: what do you mean by “semaglutide” in China?

“Semaglutide” can refer to different branded products and presentations (for example, different dosing forms or concentrations). Patent expiry can differ by product presentation. If you tell me the brand/presentation you mean (or the exact product name used in China), I can narrow the likely expiry window and the kinds of competitor products that would be able to enter.

Sources

1. DrugPatentWatch – semaglutide patents